<DOC>
	<DOCNO>NCT00024180</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop cancer cell divide stop grow die . PURPOSE : Phase I trial study effectiveness FR901228 treat patient hematologic cancer .</brief_summary>
	<brief_title>FR901228 Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine vivo biologic effect FR901228 ( depsipeptide ) patient chronic lymphocytic leukemia , small lymphocytic lymphoma , acute myeloid leukemia , acute lymphoblastic leukemia . - Determine pharmacokinetics cellular pharmacodynamics drug patient . - Determine preliminary anti-tumor activity drug patient . OUTLINE : This dose-decreasing , multicenter study . Patients stratify accord disease ( chronic lymphocytic leukemia small lymphocytic lymphoma v acute myeloid leukemia acute lymphoblastic leukemia ) . Patients receive FR901228 ( depsipeptide ) IV 4 hour day 1 , 8 , 15 . Treatment repeat every 4 week 1 year absence disease progression unacceptable toxicity . Cohorts 10 patient per stratum receive decrease dos FR901228 minimal active dose determine . If 5 patient show clinical biological response , subsequent cohort treat low dose . If few 5 patient respond , subsequent cohort treat high dose . PROJECTED ACCRUAL : A minimum 20 patient ( 10 per stratum ) accrue study .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Romidepsin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one follow hematologic malignancy : Chronic lymphocytic leukemia ( CLL ) Small lymphocytic lymphoma ( SLL ) ( include Waldenstrom 's macroglobulinemia ) Acute myeloid leukemia ( AML ) Acute lymphoblastic leukemia ( ALL ) Stratum I ( CLL SLL ) : Received least one prior therapy contain purine analog OR Received another form therapy ( include alkylating agent ) due history severe autoimmune disease , requirement chronic corticosteroid , contraindication purine analog therapy Stratum II ( AML ALL ) : Primary refractory relapse leukemia within past year amenable curative therapy OR Untreated previously treat poorrisk leukemia define follow : 65 year age Poorrisk candidate aggressive chemotherapy Poorrisk cytogenetics ( AML , karyotype abnormality ( 8 ; 21 ) , inv ( 16 ) , ( 15 ; 17 ) ) PATIENT CHARACTERISTICS : Age : 18 Performance status : ECOG 02 Life expectancy : At least 12 week Hematopoietic : Stratum I : No uncontrolled autoimmune hemolytic anemia No idiopathic thrombocytopenic purpura Stratum II : WBC great 10,000/mm^3 OR WBC great 40,000/mm^3 stable least 1 week ( may sustain hydroxyurea first week study ) Hepatic : Bilirubin great 1.5 mg/dL ALT AST great 3 time upper limit normal Renal : Creatinine le 2.0 mg/dL Cardiovascular : Ejection fraction least 50 % MUGA No myocardial infarction unstable angina within past 6 month No prior unstable ventricular supraventricular cardiac arrhythmia Other : HIV negative Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No medical psychiatric problem would preclude study Stratum I : No active infection require oral IV antibiotic PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : See Disease Characteristics At least 28 day since prior chemotherapy ( except hydroxyurea ) At least 6 week since prior nitrosoureas At least 8 week since prior UCN01 ( unless plasma UCN01 level le 1 uM ) Endocrine therapy : See Disease Characteristics Radiotherapy : At least 28 day since prior radiotherapy Surgery : At least 28 day since prior major surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2002</verification_date>
	<keyword>Waldenstr√∂m macroglobulinemia</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
</DOC>